Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 8.21 at 4:00 pm ET, low 7.95 at 11:15 am ET.
the bull case· 3
11
disclosed supplier and customer ties in SEC filings
sec filingsedgar35
managers whose positions together make up four fifths of the reported value
13fJun 30 '26+4.67%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
4 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realized6 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '263
of the funds on file reporting a position in XERS
n-portas of Jun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Xeris Biopharma Holdings, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
241 managers report a position worth $868.4M between them, and 35 of them hold 80% of it.
tall tick = annual report · 1 on record
Xeris Biopharma Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS (Xeris Biopharma Holdings, Inc.) has 11 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.